Peptide LibraryGHRP-6 dosage in published studies and labels
These are the doses used for GHRP-6 in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
GHRP-6 has published human dosing from a pharmacokinetic study that gave single intravenous bolus doses of 100, 200 and 400 mcg/kg to nine healthy male volunteers. It has also been used extensively as a diagnostic stimulus in endocrine research. All of that dosing is weight-based, intravenous and acute; no product is approved and no repeated-dosing regimen has been established.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 100-400 mcg/kg intravenous bolus (weight-based) |
| Route | Intravenous |
| Frequency | Single bolus in the published pharmacokinetic study |
| Duration studied | Acute; sampling to 12 hours post-dose |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Human pharmacokinetic study (Cabrales et al., 2013)Clinical trial · Human pharmacokinetic study | Nine male healthy volunteers | 100, 200 and 400 mcg/kg of body weight | Intravenous bolus | Single dose | Acute, with plasma sampling to 12 hours | Pharmacokinetic profile of GHRP-6 | Cabrales A et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013. |
| Endocrine comparison study (2010)Clinical trial · Human endocrine physiology study | Human subjects | Per study protocol | Intravenous | — | — | Growth hormone, ACTH and cortisol responses versus ghrelin and GHRH | Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release. Pituitary. 2010. |
| Diagnostic use in adrenal insufficiency (2010)Clinical trial · Diagnostic accuracy study | Patients assessed for adrenal insufficiency | Per test protocol | Intravenous | — | — | Diagnostic performance versus the insulin tolerance test | Diagnosis of adrenal insufficiency using the GHRP-6 test: comparison with the insulin tolerance test. Horm Metab Res. 2010. |
Where sources disagree
- Published human dosing is weight-based and intravenous. GHRP-6 is sold with fixed subcutaneous protocols commonly quoted at 100-300 mcg two or three times daily; the pharmacokinetic study's 100 mcg/kg is roughly 7 mg for a 70 kg adult, so the two are not comparable and no published study used the subcutaneous route.
- GHRP-6 reliably raises ACTH and cortisol alongside growth hormone. That is documented in the same studies used to support its growth hormone effect, and is routinely omitted from secondary sources.
- Much of the human literature uses GHRP-6 as a diagnostic stimulus in a single test, not as a treatment. A dose validated for provoking a hormone response in a clinic is not evidence for a repeated therapeutic regimen.